GSK3B and schizophrenia: The AKT‐GSK3β signaling pathway is a noncanonical D2 receptor transduction pathway that has been implicated in the pathophysiology of dopamine‐associated neuropsychiatric diseases such as schizophrenia, bipolar disorder, and depression [23, 53, 54, 55].